Format

Send to:

Choose Destination
See comment in PubMed Commons below
Crit Rev Oncol Hematol. 2013 Apr;86(1):69-84. doi: 10.1016/j.critrevonc.2012.10.001. Epub 2012 Nov 11.

Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system.

Author information

  • 1Department of Neurosurgery and Radiosurgery, IRCCS San Raffaele Scientific Institute, Milan, Italy. jody.capitanio@gmail.com

Erratum in

  • Crit Rev Oncol Hematol. 2014 Apr;90(1):91.

Abstract

Hemangioblastomas (HBs) are rare indolent vascular tumors that may occur sporadically or in association with von Hippel-Lindau (VHL) disease. Total neurosurgical resection is the standard upfront approach providing long-term tumor control. At time of tumor recurrence, second surgery, radiosurgery or radiotherapy are the main therapeutic strategies. Limited information is available on the role of pharmacological strategies. Anti-angiogenic agents, particularly multitarget tyrosine kinase inhibitors (semaxanib, sunitinib, vatalanib), thalidomide and interferon alfa-2a are currently the most widely studied strategies to prolonge disease stability. Salvage therapy with anti-angiogenetic drugs may be of benefit in some patients who are not suitable for surgery, radiosurgery or radiotherapy, with progressive or recurrent hemangioblastoma especially those located in retina, since anti-angiogenetic therapy may delay tumor progression. This strategy warrants prospective evaluation in a clinical trial.

Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

PMID:
23148943
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk